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Summary The Committee of Latin America on the Therapeutics of Inhibitor Groups (CLOTTING) is composed
of a number of hemophilia specialists from Latin America. The group aims to encourage the adoption
of a good standard of care for Latin American patients with hemophilia. The occurrence of inhibitors in patients
with hemophilia poses clinical challenges, and it is estimated that between 1.000 and 3.000 patients in Latin
America are affected by hemophilia with inhibitors. There is an urgent need to establish a regional consensus
and clinical guidelines for the diagnosis and treatment of these patients. We present an extensive review based
on best current clinical practice and published literature, as seen from a Latin American perspective, taking into
account the variable nature of hemophilia care available in the various countries in this Region.
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Resumen Diagnóstico y tratamiento de la hemofilia congénita con inhibidores. Una perspectiva latino-
americana. El Comité Latinoamericano sobre la Terapéutica de Personas con Inhibidores (CLOT-
TING) está compuesto por un grupo de especialistas en hemofilia de Latinoamérica. El objetivo del grupo es
promover la adopción de un estándar de tratamiento óptimo para los pacientes con hemofilia en Latinoamérica.
La prevalencia de inhibidores en pacientes con hemofilia en Latinoamérica determina desafíos clínicos y se estima
que de 1.000 a 3.000 pacientes en esta región están afectados con hemofilia e inhibidores. Existe una necesidad
urgente de establecer un consenso regional y guías clínicas para el diagnóstico y tratamiento de estos pacientes.
Nosotros presentamos una revisión exhaustiva basada en las mejores prácticas clínicas vigentes y en los datos
publicados en la literatura, con una perspectiva latinoamericana, tomando en cuenta la variabilidad  existente
de los tratamientos de la hemofilia disponibles en los diferentes países de esta Región.
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Hemophilia is an inherited bleeding disorder charac-
terised by frequent bleeding episodes, particularly affect-
ing joints and muscles. Treatment with clotting factors can
control the bleeding, preventing chronic arthropathy and
premature death. However, in as many as 20-30% of
patients with hemophilia A (who have a deficiency of fac-
tor VIII [FVIII]), and 3% of patients with hemophilia B (who
have a deficiency of factor IX [FIX]), replacement therapy
with coagulation factors is associated with the develop-
ment of inhibitors1, 2.
Inhibitors are neutralising antibodies that interfere with
the function of FVIII or FIX. The occurrence of inhibitors
has significant clinical implications (the response to treat-
ment becomes uncertain, morbidity is increased and life
expectancy is reduced). In addition, direct medical costs
are much higher for hemophilia patients who have inhibi-
tors, as are the non-medical costs to the patients, their
families and society3.
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Latin America (LA) has a population of around 500
million. The population is heterogeneous, and ethnic mix-
tures predominate in many countries. According to the
World Federation of Hemophilia Global Survey, in 2006
there were 20,583 hemophilia patients registered in LA4. It
is estimated that between 1,000 and 3,000 hemophilia pa-
tients in LA have inhibitors. This estimate is based on the
inhibitor prevalence reported in different Latin American
countries - at between 11% and 19% - the reported preva-
lence is similar to that described for other populations5-9.
It is recommended that national hemophilia pro-
grammes be developed; these must consider a range of
issues including: organisation and infrastructure; appro-
priate diagnosis; aims of treatment; methods of treatment;
and the products that are available10. However, many Latin
American countries do not have established national
hemophilia programmes. Indeed, mainly due to economic
reasons, the treatment of hemophilia is not a priority in
these countries. As a result, the level of hemophilia care
varies widely, and a homogeneous or standardised ap-
proach is not apparent even within individual countries;
this is particularly evident with regard to inhibitor diagno-
sis and treatment. Consequently, there is an urgent need
to establish a consensus as to how to best manage these
patients. This review was made with the purpose of facili-
tating the implementation of best practice in hemophilia
and inhibitor treatment.
The CLOTTING group
The Committee of Latin America on the Therapeutics of
Inhibitor Groups (CLOTTING) is composed of a number
of hemophilia specialists from LA. Group members are
listed in Appendix B. The objective of the group is to dis-
cuss and review the diagnosis and treatment of inhibitor
patients in LA. The group also supports the adoption of
best practice in hemophilia and inhibitor treatment, com-
municating and encouraging the improvement of
hemophilia care in the region through a constant exchange
of experiences.
A total of eight CLOTTING meetings have taken place
to prepare this review on the diagnosis and treatment of
patients with congenital hemophilia with inhibitors.
1. Diagnosis of inhibitors
1A. Inhibitor surveillance in hemophilia
According to literature data available and considering the
cost of reagents and other budget constraints in Latin
American countries, in patients with hemophilia, inhibitor
screening should take place:
- In severe and moderately severe hemophilia A, pre-
viously untreated patients should be screened for inhibi-
tors after every 5th exposition day (ED) until the 20th ED.,
then 3 to 6 monthly up to 150 ED, then once every 12
months (grade C recommendation based on level IV evi-
dence)11.
- In mild hemophilia A, screening of inhibitors is rec-
ommended after intensive replacement therapy, espe-
cially in individuals with high risk mutations (grade B level
III)11.
- Prior to any surgical or invasive procedure.
- When the clinical (or laboratory) response to con-
ventional replacement therapy is poor, or the frequency
of bleeding increases11.
- In severe and moderate hemophilia B, the frequency
of screening for inhibitors should be the same as for se-
vere hemophilia A (grade B recommendation based on
level III evidence)11.
- Following prolonged treatment with continuous infu-
sion (CI) or a high-dose therapeutic regimen.
Inhibitor screening is usually performed using activated
partial thromboplastin time (aPTT) mixing/incubation test-
ing. As FVIII inactivation by inhibitors is time and tempera-
ture dependent, the aPTT of the patient: pooled plasma
mixture should be measured and compared immediately
after mixing and after a 2-hour incubation period12.
1B. Inhibitor detection and quantification
The Bethesda assay is the recommended standard
method for measuring FVIII inhibitor titre. The same
method may also be used to quantify FIX inhibitors, but
without the 2-hour incubation (grade C recommendation
based on level IV of evidence)12.
The Nijmegen modification of the Bethesda assay can
avoid false-positive results. This is now recommended
by the International Society of Thrombosis and Haemos-
tasis (ISTH) Factor VIII/IX Scientific Subcommittee13-15.
However, as the procedure can pose an additional bur-
den when performing laboratory tests, Nijmegen modifi-
cation is sometimes considered optional; it is made only
when resources are available and at physicians’ discre-
tion.
In LA, the most important parameter evaluated with
regard to low-titre inhibitors is patients’ clinical response.
However, data relating to factor recovery and plasma half-
life may be required for the detection of low-level inhibi-
tors that reduce factor survival11. They may be performed
in selected cases, when resources are available, and also
in special circumstances, such as in the evaluation of
immune tolerance regimens.
1C. Classification of inhibitors
The ISTH classification of inhibitors16 is accepted world-
wide. Low responders have inhibitor levels <5 Bethesda
Units (BU) ml-1 and do not develop an increase in inhibi-
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tor levels after further exposure to FVIII/FIX. High respond-
ers have inhibitor titres >5 BU ml-1 or, if levels have de-
creased below this, titres that will rise to >5 BU ml-1 on re-
exposure to FVIII/FIX.
1D. Standardization and quality control
Laboratories diagnosing hemophilia and inhibitors should
standardise FVIII and FIX assays. The World Federation
of Hemophilia (WFH) laboratory manual17, or the ISTH
Factor VIII/IX Scientific Subcommittee recommendations
[available from the ISTH website]18 are valuable tools for
this purpose. An external quality assessment using World
Health Organization (WHO) coagulation standards
through the International External Quality Assessment
Scheme (IEQAS) of the WFH Laboratory Quality Control
Programme19 are also advisable in the quality control of
coagulation laboratories.
1E. Genetic diagnosis
Although some genetic defects are associated with in-
hibitor development20, molecular studies for the detection
of FVIII or FIX gene mutations are not routinely carried
out in LA.  Few centres in the region have the capability
to conduct genetic investigations on inhibitor patients.
More co-operative studies performed between hemophilia
centres in LA are needed to establish a reference data-
base of common gene defects associated with inhibitors
in the LA population. CLOTTING group members’ cen-
tres that can perform such studies are marked with an
asterisk (*) in Appendix B. Up to now, few genetic inves-
tigations have been made in the Latin American popula-
tion21-23.
2. Classification of bleeding episodes
After reviewing different definitions of bleeding severity
in the literature, bleeds occurring in patients with hemo-
philia can be classified into two categories24, 25.
Mild and moderate bleeding
In mild bleeding, signs and symptoms of hemorrhage are
evident but these do not prevent patients from perform-
ing normal activities. Patients experiencing moderate
bleeds exhibit signs and symptoms of hemorrhage and
are prevented from performing normal activities.
Examples of mild and moderate bleeding include: nose
and gum bleeds without hemodynamic repercussions;
soft-tissue bleeds and superficial skin cuts; acute hemar-
throses; peripheral muscular hematomas; hematuria; and
bleeding without hemodynamic repercussions associated
with dental extraction.
Severe bleeding
This is defined as any bleeding that poses a risk to life,
limb, or an important function (life- or limb-threatening
hemorrhages). Examples include: bleeding associated
with the central nervous system, thoraco-abdominal and
retroperitoneal bleeds; gastrointestinal bleeds; neck and
throat bleeds; large hemarthroses and large muscular
hematomas (iliopsoas hemorrhage or bleeding causing
compartment syndrome); opthalmic (intra-ocular) he-
morrhages; severe trauma; and any external/internal
bleeding with hemodynamic repercussions. Any bleed-
ing in hemophiliac patients, particularly patients with in-
hibitors, could be severe (life- or limb-threatening) if it is
not immediately treated.
3. Treatment of bleeding episodes in congenital
hemophilia A with inhibitors
The management of acute bleeds in hemophilia A pa-
tients with inhibitors depends on the severity of the bleed,
the inhibitor titre at the time of bleeding and any known
anamnestic response. When choosing a treatment op-
tion, the efficacy, safety and availability of the therapy
should also be considered. Hemostatic treatment should
be initiated as soon as possible.
3A. Mild and moderate bleeding episodes
Due to a limited number of randomised clinical trials evalu-
ating treatment options for inhibitor patients in different
clinical settings, a review of current management of bleed-
ing in patients with congenital hemophilia A and inhibi-
tors is made available in the tables below.
3Ai. Low responders (Table 1)11, 26-28
3Aii. High responders11, 26-38
Recombinant activated factor VII (rFVIIa; NovoSeven®,
Novo Nordisk, Bagsvaerd, Denmark) and activated pro-
thrombin complex concentrate (aPCC; FEIBA®, Baxter,
Deerfield, IL, USA) are the preferred bypassing agents
for mild and moderate bleeds in high-responder patients.
Efficacy rates with these agents are around 79-92%29-32.
A recent head-to-head comparison between both treat-
ments has just been published showing that aPCC and
rFVIIa appear to have a similar effect on joint bleeds al-
though the efficacy between products is rated differently
by a substantial proportion of patients33. However, Young
et al demonstrated that rFVIIa 270 µg/kg and rFVIIa 90
µg/kg (x3 doses) reduces the need for rescue medication
compared to aPCC suggesting it to be potentially more
effective treatment option than aPCC for home treatment
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joint bleeds34. In addition, Ozelo et al, demonstrated that
rFVIIa resolve bleeds more quickly (4.4 hs.) than aPCC
(62.6 hs.) and was more effective (100% vs. 57.7% re-
spectively)35. Megadoses of rFVIIa (doses >200 µg kg-1
body weight) are being used in inhibitor patients for mild
and moderate bleeding as a convenient means of avoiding
repeated injections, particularly in children. Although this is
a non-approved use, it has been extensively tested without
any safety concerns34, 35. In a recent trial, comparing three
standard doses of rFVIIa 90 µg kg-1 body weight every 3
hours with a single dose of rFVIIa 270 µg kg-1 in the home
setting, administration of the single high dose of rFVIIa had
comparable efficacy and safety to standard dosing, and no
thromboembolic events were reported (Table 2)34, 36, 37. When
these options are not available, non-activated prothrombin
complex concentrates (PCCs) can be used. The usual dose
of these is 50–75 U kg-1 body weight every 12 hours. Effi-
cacy rates in randomised clinical trials performed in the early
1980s were around 50%27, 40, 41.
3B. Severe bleeding episodes
In instances of severe bleeding, the duration of treatment
must be considered for each case on an individual basis
and therapy should subsequently be evaluated accord-
ing to the clinical response. In addition, prophylaxis
scheme should be consider according to the type and
severity of bleeding42.
TABLA 1.– Treatment of mild and moderate bleeding in hemophilia A patients
with low-response inhibitors
Second option
If there is no response to high-dose FVIII
(persistent bleeding) due to an inability to
maintain adequate FVIII: C levels (>30 IU
dl-1 has been recommended)
Increase doses 2×
or
Switch to high-responder treatment
First option
High-dose FVIII
FVIII 50-100 IU kg-1 body weight as a bolus
every 12-24 hours
For as long as is judged necessary to
control bleeding (approx. 1-3 days)
FVIII, factor VIII
TABLA 2.– Treatment of mild and moderate bleeding in hemophilia A patients
with high-response inhibitors
Second option
If there is no response to treatment (per-
sistent bleeding):
Increase doses
or
Switch to the other treatment option
First option
rFVIIa
Children: 90-120 µg kg-1 body weight as a
bolus every 1.5-2 hours
Adults: 90-120 µg kg-1 body weight as a
bolus every 2–3 hours
For as long as is judged necessary to con-
trol bleeding (approx. 1-4 doses). Single
dose: 270 µg kg-1 body weight
or
aPCC
50-100 U kg-1 body weight every 12 hours
For as long as is judged necessary to
control bleeding (approx. 1-4 doses)
aPCC, activated prothrombin complex concentrate; rFVIIa, recombinant activated factor VII
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3Bi. Low responders and high responders with an
initially low titre (<5 BU ml-1)14, 26-28
It has been recommended to maintain FVIII:C levels >30
IU dl-1 when using high doses of FVIII as the first option
for low-responder or high-responder patients with an ini-
tially low titre27. When choosing high doses of FVIII or
aPCC as the first option for high-responder inhibitor pa-
tients who have a low titre at the beginning of treatment,
the risk of developing an anamnestic response must be
considered (Table 3)27, 28, 32.
3Bii. High responders (Table 4)14, 26-38, 42, 43
The concomitant use of antifibrinolytics is discussed in
Section 9A.
4. Treatment of bleeding episodes in congenital
hemophilia B with inhibitors
Treatment options for patients with congenital hemophilia
B and inhibitors will depend on the severity of the bleed
and the past history of anamnestic response. Patients
with hemophilia B and inhibitors can exhibit allergic re-
actions following FIX administration; this is particularly
possible in patients with large gene deletions44. The al-
lergic reaction includes urticaria, rash, angio-oedema,
bronchospasm, hypotension or acute anaphylaxis. The
reactions can appear at the same time as the inhibitor
(median of 11 days of exposure), and after infusion of
both high- and low-purity FIX concentrates14. An asso-
ciation between allergic reactions and nephrotic syn-
drome has been reported during immune tolerance in-
duction with FIX44-46. Consequently, the possibility of
patients experiencing anaphylaxis or other allergic re-
actions should be considered when selecting FIX-con-
taining products.
4A. Patients without a history of allergic reactions
Low-titre inhibitor patients may respond to high-purity FIX.
For mild and moderate bleeds, the initial recommended
dose is 100-200 IU kg-1 body weight, followed by 50-100
IU kg-1 body weight every 12 or 24 hours for as long as is
judged necessary to control the bleeding (usually 1-3
days). In cases of inadequate response, treatment should
be changed to bypassing agents.
Severe bleeds or high-responder patients should be
treated with bypassing agents using doses similar to those
described for patients with FVIII inhibitors (Tables 2 and
4). The risk of anamnesis and anaphylaxis should be borne
in mind when choosing aPCC to treat patients with
hemophilia B and inhibitors. rFVIIa might be considered
the treatment of choice for acute bleeds14, 28.
4B. Patients with a history of allergic reactions
Because of the possible recurrence of allergic reactions
following FIX administration, rFVIIa is recommended as
the treatment of choice in this group of patients14, 28. Doses
FVIII, factor VIII
aNeutralising dose = inhibitor titre (BU) × plasma volume (mL)
bIncremental dose = 30–100 IU kg-1 body weight (depending on bleeding severity)
cThe duration of treatment must be individualised and evaluated according to clinical response.
Second option
If there is no response to high dose FVIII
(persistent bleeding) or if inhibitor titre
increases:
Change to treatment of severe bleeding in
high-responder patients
TABLA 3.– Treatment of severe bleeding in hemophilia A patients with low-response
inhibitors or high-response inhibitors with an initially low titre
First option
High-dose FVIII
Initial dose:
100 IU kg-1 body weight
or
Neutralisinga + incremental doseb
Maintenance:
50-100 IU kg-1 body weight every 8-12
hours
or
Continuous infusion 10 IU kg-1 body weight
hr-1
For as long as is judged necessary to
control bleedingc
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are similar to those used for hemophilia A patients with
inhibitors. If the requirement for treatment is urgent and
rFVIIa is not available, FIX-containing products may be
used with extreme caution under medical supervision. Pre-
medication with antihistamines and steroids is recom-
mended, together with adequate conditions for the treat-
ment of acute allergic reactions and anaphylaxis14.
5. Home treatment for mild and moderate bleeds
Early studies demonstrated the significant quality-of-life
benefits associated with home treatment47-50. Home infu-
sion of coagulation factors significantly decreased hospi-
tal admissions due to bleeding complications; it also de-
creased pain, dysfunction and long-term disability47-52. In
patients with hemophilia and inhibitors, home treatment
of mild and moderate bleeds has shown results similar to
those found in patients without inhibitors29-32.
While the introduction of home treatment undoubtedly
motivates patients and contributes positively to quality of
life, properly performed self-management also puts de-
mands on patients in terms of observation, judgement
and skilled reporting. To meet these demands, patients
should comply with recommendations and co-operate with
treatment centre staff. Ideally, patients should be alert to
the onset of new bleeding episodes and capable of tak-
ing action immediately. When selected for this modality,
patients should be taught to understand the properties of
products prescribed. Even for highly skilled patients, com-
plete training and instructions should be given concern-
ing product storage, product reconstitution and a practi-
cal approach to self-injection.
rFVIIa/aPCC home-treatment programmes require the
education of patients and their families in relation to dose,
administration frequency and evaluation of response.
Such programmes must be designed and closely moni-
tored by hemophilia treatment centres. Home-treatment
training should be continuously validated by hemophilia
centre staff. It is particularly important that patients un-
derstand product characteristics, especially the short half-
life of rFVIIa and the requirement for repeated dosing at
regular intervals when appropriate, so that additional dos-
ing is not unduly delayed53. Patients should contact their
treatment centres for advice in any cases of doubt or if
treatment appears to be ineffective.
It is recommended that patients make a registry of all
bleeding episodes treated at home. The bleeding site,
time of onset, treatment used and duration should be prop-
erly recorded by patients or their caregivers and commu-
nicated to the hemophilia centres.
Hemophilia centres should be capable of supplying
sufficient quantities of product to completely treat mild
and moderate bleeding and to begin the treatment of se-
vere bleeding in cases of emergency. They should also
provide patients with appropriate advice and support on
a 24-hour basis. Measures should be taken to ensure the
proper running of home-treatment programmes, with ad-
equate stocks and easy delivery of concentrates being
required to realise the full benefits of this treatment mo-
dality53.
Infusion sets (syringes, needles and vials) should be
properly discarded as they contain biological material.
Patients should place items in appropriate, safe, dispos-
able boxes, if possible provided by the hemophilia cen-
tre. If safe disposal by patients cannot be assured, it is
recommended that material is returned to hemophilia
centres for adequate disposal.
Like in non-inhibitor patients, treatment should start
as early as possible, preferably less than 2 hours after
symptoms become apparent.
Based on the review made, appropriate dosage rec-
ommendations for the treatment of mild and moderate
bleeds are given in Tables 1 and 2. According to the treat-
ment response, 1-4 doses are generally required. How-
ever, if an effective response is not apparent after the
first two doses, patients should contact their treatment
centres for instructions.
6. Prophylaxis for patients with congenital hemophilia
and inhibitors
Currently, there is no clinical evidence in the literature to
determine whether prophylaxis is more effective than on-
demand treatment for hemophilia patients with inhibitors.
Attempts to establish a prophylactic regimen for inhibitor
patients with frequent bleeds (secondary prophylaxis)
have been carried out using bypassing agents (both rFVIIa
and aPCC) with the objective of decreasing the number
of recurrent bleeds and allowing the rehabilitation of tar-
get joints. Further information is required with regard to
minimum effective doses, dosing frequency, and safety
aspects relating to prolonged use of these agents in
prophylaxis54-59.
6A. Prophylaxis with rFVIIa
Isolated case reports using rFVIIa as prophylaxis in high-
responder inhibitor patients have been described using
different doses (ranging from 90 µg kg-1 body weight daily,
to 200 µg kg-1 body weight every 6 hours for prolonged
periods), with variable results. A multi-centre, randomized,
prospective trial evaluating the efficacy and safety of rFVIIa
for secondary prophylaxis in inhibitor patients has just
been finalized. It showed that rFVIIa dosed once-daily in
inhibitor patients with frequent bleeds, either with 90 µg
kg-1 body weight or 270 µg kg-1 body weight, resulted in
clinically relevant reductions in number of bleeds and
improvements in quality of life during prophylaxis com-
pared with conventional on-demand therapy, without rais-
ing any safety concerns54-56. Hoots et al, recently pub-
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lished the results of a prospective trial showed that sec-
ondary prophylaxis with rFVIIa may provide an alterna-
tive treatment modality to conventional treatment in pa-
tients with frequent bleeds related to health-related qual-
ity of life (HRQoL) improvement57.
6B. Prophylaxis with aPCC
Retrospective studies and case reports have described
the prophylactic use of aPCC, particularly for late post-
surgical or severe bleeding episodes, for physical therapy
or rehabilitation, and to prevent recurrent haemarthroses
in target joints, e.g. during immune tolerance induction.
Doses are similar to those recommended for bleeding
episodes (50-100 U kg-1 body weight), administered three
times a week, or every other day. Results have shown a
reduction of up to 50% in the number of joint bleeds, to-
gether with the prevention of severe hemorrhages58, 59.
Leissinger et al, described 5 patients under prophylaxis,
dosages ranged from 50 to 75 U kg-1 three times a week
in four patients and 100 U kg-1 daily in one patient. This
short case series suggest thats prophylaxis with aPCC
may be an option for decreasing the number of bleeding
episodes60.
7. Surgery in congenital hemophilia with inhibitors
Surgery in patients with hemophilia and inhibitors is al-
ways a high-risk procedure. It should be carried out at
experienced centres by skilled surgeons, under the su-
pervision of a hematologist. Involvement of a multidisci-
plinary team is required both before and after the sur-
gery. Hemostasis must be adequate throughout the en-
tire procedure, and for a period of days afterwards to al-
low wound healing. Elective surgery requires excellent
pre-surgical evaluation and appropriate information, both
for patients and their families. Enough factor concentrate
should be available to cover the entire treatment and any
possible ensuing complications. It is also important that a
hemostasis laboratory be involved in determining the ap-
propriate dosage of coagulation factor, and the detection
and quantification of inhibitors. Pharmacokinetic (PK) stud-
ies, for both adults and children, are not routinely per-
formed in inhibitor patients in the surgical setting. How-
ever, PK information can be useful when performing sur-
gery in low-responder patients. When conducting surgery
under rFVIIa coverage, it may also be appropriate to per-
form PK evaluations before the surgery, as individual re-
sponses, namely half-life and clearance, are variable,
particularly in younger patients61, 62.
Two types of surgical interventions have been reported
in the literature - minor and major. However, no clear
definition of these has been published to date63. The dif-
ferentiation between major and minor procedures is based
on the extent of replacement material necessary for
fibroblast growth and good scar formation64. Minor sur-
gery may be considered to involve procedures that do not
penetrate a body cavity or transect a major limb bone, and
major surgery may be regarded as any type of thoraco-
abdominal, intracranial or orthopedic surgery65, 66. Based
on the available literature, the classification of minor sur-
gery should include only those procedures requiring small
skin excisions and/or small sutures66. All the other proce-
dures should be classified as major surgery. Among or-
thopedic procedures, only synoviorthesis and arthrocen-
tesis are classified as minor63-66.
There has been no agreement to evaluate efficacy
parameters relating to the hemostatic response to substi-
tution therapy after surgical procedures. Effective
hemostasis is generally assessed in terms of physicians’
clinical judgement. A clinical trial of surgery in inhibitor
patients used the following definitions67:
- Treatment is rated as effective if bleeding is prevented
during surgical intervention.
- Treatment is rated as partially effective if the bleed-
ing is only partially prevented during surgical interven-
tion.
- Treatment is rated as ineffective if bleeding cannot
be prevented during surgical intervention.
Recent literature reviews have suggested that, with
the options available, it is possible to achieve adequate
hemostasis, with a very low rate of side effects, during
elective surgery in patients with inhibitors68, 69. Both rFVIIa
and aPCC have demonstrated efficacy rates between 80%
and 90%, or even higher, although optimal doses and
dosing intervals have not been clearly established69-72.
Ingerslev et al and  Obergfell et al reviewed the data on
elective orthopedic surgeries  in hemophilia patients with
inhibitors under cover of rFVIIa. These authors highlight
the relevance of rFVIIa in elective orthopedic surgery re-
garding the safety and efficacy according to the published
experience particularly in major procedures73, 74.
It is extremely important to have enough factor con-
centrate to cover the entire treatment and to avoid com-
plications. If possible, it is recommended to have both
options available before deciding on major elective sur-
gery.
Porcine FVIII was not included in this review because
it has been recently discontinued and is no longer avail-
able in the market. A recombinant porcine factor VIII is
being investigated in clinical trials.
In this review, recommendations for surgery in patients
with congenital hemophilia and inhibitors are similar to
those for severe bleeding (Tables 3 and 4) with some
important qualifications:
i. The inhibitor should be quantified prior to any surgi-
cal procedure.
ii. Preferably, elective surgery in inhibitor patients
should be scheduled for the beginning of the week and
not be carried out before weekends or holidays.
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iii. When choosing high doses of FVIII or aPCC as a
first option for the high-responder inhibitor patient with a
low titre at the beginning of treatment, the risk of develop-
ing an anamnestic response must be considered27, 28, 32.
iv. Initial (pre-operative) dosing should be performed
immediately before the beginning of surgery, preferably
in the operating room during induction anaesthesia.
v. It has been recommended to maintain FVIII:C lev-
els >50 IU dl-1 when using high doses of FVIII as a first
option for low-responder or high-responder hemophilia A
patients with an initially low inhibitor titre27.
vi. As there is not enough evidence to recommend the
use of high doses of FIX in surgery for low-responder or
high-responder hemophilia B patients with an initially low
inhibitor titre, bypassing agents are recommended.
vii. In surgery for hemophilia patients, sutures are pre-
ferred over cauterization of small vessels.
viii. The duration of treatment depends on the type of
surgery. In general, treatment periods of 1-5 days for mi-
nor surgery and 7-14 days for major surgery are adequate.
ix. In cases of bleeding, or if treatment is partially ef-
fective, a surgical cause should be excluded. If there is
persistent bleeding despite control of a surgical cause,
the treatment should be modified by increasing the dose
or changing the treatment option.
x. Central venous access devices (CVAD) are often
used for hemophilia patients with inhibitors under immune
tolerance therapy (ITT). Although external catheters such
as the Hickman® and Broviac® (Bard Access Systems,
Inc., Salt Lake City, Utah, USA), have frequently been
used for ITT in hemophilia patients, there is a growing
evidence that inhibitor patients with fully implantable cath-
eters (portacaths) have fewer catheter-related infections.
This suggests that ports may also be preferable, unless
TABLA 4.– Treatment of severe bleeding in hemophilia A patients
with high-response inhibitors
aPCC, activated prothrombin complex concentrate; rFVIIa, recombinant activated factor VII
aThe duration of treatment must be individualised and evaluated according to the clinical response.
bSequential treatment combining rFVIIa and aPCC has been described with good results, in cases of severe
bleeding and lack of therapeutic response with a single bypassing agent. This consists of an initial dose of
aPCC (mean dose 55 U kg-1 body weight) followed 6 hours later by 1-3 doses of rFVIIa every 2 hours (mean
dose 164 μg kg-1 body weight) before the next dose of aPCC 6 hours after the first rFVIIa dose, with these
treatments then being administered successively40.
cConcomitant treatment was described by Martinowitz and colleagues for patients refractory to high doses
of rFVIIa or aPPC43. This consists of a combination of 30-70 μg kg-1 body weight of rFVIIa and 20-30 U kg-1
body weight of aPCC. Clinical responses were markedly improved following this combination dose and a
total of 90 bleeding episodes were treated, with excellent haemostatic effects in most instances.
dIf the mentioned treatment options fail or are not available, it is recommended to start therapeutic
plasmapheresis, with or without extracorporeal protein A immuno-adsorption, to decrease the inhibitor titre,
followed by treatment with high dose FVIII as described 27, 28.
Second option
If there is no response to treatment
(persistent bleeding):
Increase doses or switch to the other
treatment option
or
Sequential treatment with rFVIIa and
aPCCb
or
Therapeutic plasmapheresis followed by
high-dose FVIIId
First option
rFVIIa
Children: 90–120 µg kg-1 body weight as a
bolus every 1.5–2 hours for the first 24–48
hours (children may require higher initial
doses); then gradually prolong the intervals
in the following days (every 2, 3 or 4 hours)
Adults: 90–120 µg kg-1 body weight as a
bolus every 2–3 hours for the first 24–48
hours; then gradually prolong the intervals
in the following days (every 3, 4 or 6 hours)
For as long as is judged necessary to
control bleedinga
or
aPCC
Maximum of 200 U kg-1 body weight day-1
divided in 2–3 doses
For as long as is judged necessary to
control bleedinga
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the advantages of external catheters are important for
particular individuals according to physicians’ judgement75.
Several haemostatic coverage regimens at the time of
CVAD placement and removal have been described. Ef-
fective replacement treatment during CVAD insertion was
generally obtained using rFVIIa or aPCC. The usual the
duration of treatment is 2-3 days76-78.
xi. The management of dental procedures is subject
to the same recommendations relating to the type of
anesthesia used and local measures, for both hemophilia
patients with and without inhibitors. Replacement therapy
is recommended whenever general anesthesia with en-
dotracheal intubation or nerve trunk infiltration is going
to be performed. Truncal anesthesia carries the risk of
life-threatening cervical bleeding for inhibitor patients. A
careful approach by a skilled dentist and more prolonged
factor replacement than a single pre-procedure dose is
recommended. For dental extraction, the same replace-
ment therapy as for a minor surgery is recommended,
although this is normally necessary for only 24–48 hours.
Local hemostatic measures, such as adequate suturing,
use of fibrin glue and use of systemic antifibrinolytic
agents, if not contraindicated, should always be employed.
xii. When invasive diagnostic procedures (such as lum-
bar puncture, arterial puncture, bronchoscopy with brush-
ing or biopsy, or gastrointestinal endoscopy with biopsy)
are performed in inhibitor patients, replacement therapy
with at least a single dose of coagulation factor immedi-
ately prior to the procedure is recommended. However,
considering the high risk of serious complications in these
procedures, especially lumbar punctures, 2-3 additional
doses after the procedure can be necessary.
A consensus on orthopedic surgery in inhibitor patients
was published by a panel of experts63. The recommenda-
tions (shown in the adapted table below) were made in
order to obtain effective hemostasis during these proce-
dures and can be used as another option for surgery in
patients with inhibitors (Table 5). Occasionally, unsatis-
factory results have been observed with conventional
doses of bypassing agents, particularly in orthopedic sur-
gery. Based on both published case series and personal
experience, some authors have described the use of
higher than recommended doses of rFVIIa and aPCC32,
72, 79
.
8. Immune tolerance induction (ITI)
ITI is a strategy to desensitise patients’ immune systems
to extrinsic FVIII or FIX by repeated intensive exposure
to this antigen. This approach is successful in eliminating
TABLE 5.–  Recommended dosage of recombinant activated factor VII (rFVIIa) and activated prothrombin
complex concentrate (aPCC) for surgery (adapted from data taken from Rodriguez-Merchan et al.)63
Type of Pre-operativea Days 1-5 Days 6–14
surgery
Minor rFVIIa rFVIIa
surgery Adults: 90–120 µg kg-1 90–120 µg kg-1 body
body weight weight every 2 hours for 4
Children: 120-150 µg doses and then every 3-6 hours
kg-1 body weight
or or
aPCC aPCC
50-75 U kg-1 body 50-75 U kg-1 body weight
weight  every 12-24 hours
Major rFVIIa rFVIIa rFVIIa
surgery Adults: 120 µg kg-1 90-120 µg kg-1 body 90-120 µg kg-1 body weight
body weight weight every 2 hours for 24  every 6 hours
Children: 150 µg kg-1  hours, every 3 hours on or
body weight Day 2, and then every 4 aPCC
or hours on Days 3-5 75-100 U kg-1 body weight
aPCC or every 12 hours
75-100 U kg-1 body aPCC
weight 75-100 U kg-1 body weight
every 8-12 hours
aThe initial (pre-operative) dose should be administered immediately before the beginning of surgery, preferably in the operating
room during induction anaesthesia.
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the inhibitor permanently in around 80% of inhibitor pa-
tients. ITI may take 1-3 years to achieve tolerance, at a
cost of approximately 1 million US$ per patient80. ITI is
recommended for high-responder inhibitor patients.
Although it is almost 30 years since the first experi-
ence of the induction of tolerance (at Bonn, Germany)81,
the mode of action of ITI is still not fully understood, and
little is known about the mechanism by which immune
tolerance is achieved. Future immunologically based stud-
ies are needed to clarify this. Various mechanisms have
been proposed to explain the effect of repeated intensive
exposure of FVIII or FIX on immune system. Down-regu-
lation of the immune response to factor VIII and long-
lasting tolerance could be induced by anti-idiotypic anti-
bodies neutralising anti-FVIII antibodies, the deletion of
antigen-specific T cell clones or inducing the develop-
ment of regulatory T-suppressor cells82.
Protocols combining intensive FVIII or FIX replacement
with concomitant immunosuppression exist. The Malmö
regimen, in which high-dose FVIII or FIX replacement is
combined with cyclophosphamide, high-dose immu-
noglobulin and protein A immuno-adsortion, is the best-
known example of these83. The use of immunosuppres-
sive agents such as the anti-CD 20 monoclonal antibody,
rituximab, has also been reported in the treatment of in-
hibitor patients84-87.
Regimens of ITI are the only available treatments that
eradicate alloantibodies to FVIII or FIX, and these remain
the best long-term option, particularly for high-titre anti-
bodies88. Inhibitor eradication with ITI leads to a marked
improvement in patients’ quality of life and may consider-
ably reduce the cost of future treatment.
Data relating to ITI have been collated in several reg-
istries. These include the International Immune Tolerance
Registry (IITR)89 the North American Immune Tolerance
Registry (NAITR)90, the German91 and the Spanish92 reg-
istries. The overall success rate of ITI in all these regis-
tries is comparable, at 75 ± 10%. Favourable indicators
and adverse risk factors relating to outcomes in ITI have
been identified using the accumulated data. Recently, Di
Michele et al, published a consensus recommendation
on immune tolerance induction based on the level of avail-
able supporting evidence93.
There is agreement that a low-inhibitor titre prior to
the initiation of ITI (<10 BU ml-1) and a low historical peak
inhibitor titre (<200 BU ml-1) are favourable clinical fea-
tures. However, there is some disagreement as to whether
patient age at the initiation of ITI, or the time between
inhibitor diagnosis and starting ITI, predicts successful
outcome (Table 6).
The study cohorts, as well as the immune tolerance
regimens, differ in many respects, including the dosage
of FVIII, the number of infusions of factor concentrate per
day, the type of factor concentrate, the association with
immunosuppressive drugs and the definition of success
of ITI82. The influence of the type of product used has not
been well established. Although Kreuz and colleagues have
suggested that successful immune tolerance may be
achieved using intermediate-purity FVIII concentrate94, re-
cent results suggest good efficacy may be obtained using
high-purity products or recombinant FVIII (rFVIII)95, 96. Suc-
cess rates in these studies are similar, although the me-
dian time to success differs.
Low-dose ITI is a less-demanding protocol in which
patients have to be infused only two or three times a week.
As the amount of FVIII infused is lower, such a regimen
may be initially more attractive for economic reasons.
However, one disadvantage as compared to high-dose
TABLE 6.– Immune tolerance induction - influence of factor VIII (FVIII) dose or
immunosuppression on success rate [adapted from data taken from DiMichele 200290
and DiMichele 200388 and DiMichele 200793]
Protocol Adjuvant FVIII dose Median Success rate
therapy  treatment (%)
time (months)
Bonn None 200-300 IU kg-1 day-1 15.0 73
Cy
Malmö IvIg 200 IU kg-1 day-1 01.3 80
Im Ads
25 IU kg-1 dose-1
Dutch None
3 × week 11.5 83
Kasper Cy or Pdn 50 IU kg-1 day-1 3.0 73
Cy, cyclophosphamide; Im Ads, plasmapheresis and extracorporeal protein A immuno-adsorption; IVIg,
intravenous Immunoglobulin G; Pdn, prednisone
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ITI regimens, is that patients may need to be treated for
longer periods of time before tolerance is achieved97.
ITI has been carried out in LA with either a modified
high-dose protocol98, 99 or the low-dose Dutch protocol
using FVIII/von Willebrand factor (VWF) concentrate (30
IU kg-1 body weight three times weekly)100. Results are
similar to those published in the literature, and co-opera-
tive studies in the region are encouraged.
A central venous catheter is usually used when ITI is
carried out, particularly in children whose regimens re-
quire daily, or several weekly, doses. Infection in this line
is a common complication and is related to an anamnes-
tic increase in inhibitor titre93, 96.
Relapses following successful ITI are reported, but they
appear to be infrequent. The International Registry re-
ports 6 relapses in 128 patients in whom ITI was suc-
cessful. The relapse rate was 15% at 15 years101.
Experience with ITI for hemophilia B patients with inhibi-
tors is limited. The principles of treatment for these patients
are similar to those for hemophilia A. However, the success
rate is lower, regimens are associated with a risk of anaphy-
laxis to FIX, and irreversible nephrotic syndrome can oc-
cur46, 102. Recently, DiMichele et al, concluded that there can
be no recommendations for ITI in hemophilia B93.
9. Special considerations
9A. Use of antifibrinolytics
Concomitant use of antifibrinolytics and bypassing agents
during bleeding or surgery has not been investigated in
clinical trials. However, some authors have suggested that
the use of systemic antifibrinolytics, particularly tranexamic
acid, together with rFVIIa is safe, and can help to prevent
bleeding30, 71, 103, 104. This could be recommended for mu-
cosal bleeding (with a mouthwash being a possibility here)
and orthopedic surgery, unless there is a known contrain-
dication such as urinary bleeding or suspected dissemi-
nated intravascular coagulation. Concurrent systemic
antifibrinolyitic therapy with aPCC is generally avoided, and
there is no evidence relating to the safety of this. At least a
12-hour interval between the last dose of aPCC and the
use of systemic antifibrinolytics should be considered.
Recommended antifibrinolytic doses:
- Tranexamic acid: 25 mg kg-1 body weight every 8
hours PO or 15 mg kg-1 body weight every 8 hours IV;
mouth wash at 10% solution.
- Epsilon amino caproic acid: 50-100 mg kg-1 body weight
every 6 hours PO or IV (maximum dose is 24 g day-1).
9B. Continuous infusion (CI) of rFVIIa
Although some evidence of the efficacy rFVIIa adminis-
tered by CI has been published, more studies are needed
to allow the recommendation of this treatment modality.
As for FVIII and FIX, the rationale behind CI with rFVIIa is a
consequence of its convenience (because its short half-life
and requirement for frequent dosing) and the potential cost-
effectiveness associated with a reduced total dose103-105. Al-
though FVII:C levels attained in plasma are not always pre-
dictive of efficacy, surgical efficacy rates greater than 90%
have been obtained with an initial bolus dose of 90-120 µg
kg-1 body weight, followed by CI of 10-50 µg kg-1 h-1, aiming
at a FVII:C level of 20-30 IU ml-1 106-109. However, cost ad-
vantages have still to be demonstrated, particularly when
additional bolus doses are required to control bleeding109.
9C. Laboratory monitoring
Currently, there is no measurable laboratory parameter
for monitoring the efficacy of bypassing agents. Assays
using non-flow techniques, like prothrombin time (PT) and
aPTT, have limited application in the monitoring of these
agents and do not reflect physiological conditions110. For
rFVIIa, using either bolus dosing or CI, FVII:C levels do
not generally correlate closely with the clinical response107.
Experimental models using whole blood, and indirectly
measuring thrombin generation, may have a role in the
monitoring of bypassing agents107.  Young and co-work-
ers, suggested that thromboelastography may potentially
be a clinically useful tool for monitoring changing concen-
trations of recombinant activated factor VII in hemophilia
patients, but only when the baseline curve is significantly
abnormal111. On the other hand,  Lak et al, showed that
ROTEM® should not be the method of choice for monitor-
ing rFVIIa therapy in Glanzmann patients112.
Investigations are being carried out using thromboelas-
tography and thrombin generation assays (TGA), but
standardization and validation is currently lacking113, 114.
Treatment efficacy during bleeding and surgery is usu-
ally judged clinically.
9D. Adverse events with hemostatic drugs
Antifibrinolytics: These drugs inhibit plasmin genera-
tion and activity. Adverse events include: allergic reac-
tions; nausea; diarrhoea; hypotension; and fatigue. It is
necessary to be wary of the use of these drugs in pa-
tients with kidney failure, haematuria, cardiopathy or liver
disease. Rapid intravenous administration must be
avoided as this can result in hypotension and cardiac
arrhythmias.
aPCCs: As these products are obtained from human
plasma, the risk of transmission of infectious agents should
be considered. However, for known human pathogens,
this risk is very low. Mild or moderate adverse events in-
clude cutaneous rashes and anaphylactic reactions. If
allergic reactions do occur, the use of aPCCs should be
suspended, with steroids and antihistamines being ad-
ministered. The most serious adverse events occurring
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during treatment with aPCCs are thromboembolic events,
especially myocardial infarction; this may occur particu-
larly after the use of high doses of aPCC. Alterations in
the results of laboratory tests and/or occasional signs of
disseminated intravascular coagulation can appear after
administration of these agents. aPCCs should not be used
with systemic antifibrinolytics because of the risk of throm-
botic complications.
rFVIIa: Non-serious adverse events are rare and those
most frequently reported are: pain at the injection site;
fever; migraine; vomiting; fluctuations in arterial pressure;
and cutaneous reactions of hypersensitivity. Serious treat-
ment-related adverse events tend to be thromboembolic
in nature, mainly myocardial or cerebral infarctions, or
pulmonary embolisms.
In general, thrombotic complications are rare with both
aPCCs and rFVIIa. However, these agents should be used
with caution in patients who have a high thrombotic
risk59, 70, 115-117.
Concluding comments
Latin American countries share common economic and
social problems. In many of these countries obtaining
products for the treatment of hemophilia has not been a
priority, resulting in a lack of adequate treatment, and
ensuing serious consequences, for patients with
hemophilia. However, in recent years, some countries in
LA have made huge efforts to improve the care of these
patients, developing a national programme and acquir-
ing increasing amounts of therapeutic products to attend
to patients’ needs. Despite this improvement, the ex-
change of best practices is not routine within the region
and many hemophilia centres seek specialised support
from experts from developed countries. The situation is
gradually changing as good results from local initiatives
begin to appear, and proper support for the treatment of
patients with hemophilia can be obtained in neighbour-
ing countries.
One of the objectives of the CLOTTING group is to
communicate and encourage the adoption of a good
standard of hemophilia care in LA. The purpose of this
review is to create awareness of the management of in-
hibitors in patients with hemophilia. Inhibitors pose seri-
ous challenges for physicians, and for patients and their
families. Therefore there is an urgent need to know how
to properly manage these patients.
The opportunity to share experiences is extremely
important in creating the necessary motivation for estab-
lishing proper inhibitor treatment. This was attained dur-
ing the preparation of this document. As a result, the
CLOTTING review is based on best current practice and
updated published literature as seen from the perspec-
tive of Latin American hemophilia specialists.
Conflict of interest: CLOTTING group activities and meet-
ings are supported by an unrestricted educational grant from
the Novo Nordisk Latin America Regional Office and affiliates.
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Appendix A
Levels of evidence and grading of recommendations based on AHCPR118, 1992.
Level Type of evidence
Ia Evidence obtained from meta-analysis of randomised studies
Ib Evidence obtained from at least one randomised controlled trial
IIa Evidence obtained from at least one well-designed controlled study without randomisation
IIb Evidence obtained from at least one other type of well-designed quasi-experimental study
III Evidence obtained from well-designed non-experimental descriptive studies, such as comparative studies,
correlation studies and case control studies.
IV Evidence obtained from expert committee reports or opinions and/or clinical experience of respected authorities
Grade Recommendations
A (Ia,Ib) Requires at least one randomised controlled trial as part of the body of literature of overall good quality and
consistency addressing the specific recommendation.
B (IIa, Requires availability of well-conducted clinical studies but no randomised clinical trials on the topic of the
recommendation.
C (IV) Requires evidence from expert committee reports or opinions and/or clinical experience of respected authorities.
Indicates absence of directly applicable studies of good quality.
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